fogsprayhk
Pentetreotide | CAS 138661-02-6 | Radiolabeled Somatostatin Analog for Neuroendocrine Tumor Imaging
Product Description
Pentetreotide is a synthetic peptide conjugated with diethylenetriaminepentaacetic acid (DTPA), engineered to facilitate chelation with radioisotopes such as indium-111 for molecular imaging applications. Functionally, it mimics the pharmacological properties of somatostatin, a natural peptide hormone that inhibits the release of various growth and neuroendocrine factors.
By radiolabeling Pentetreotide with indium, researchers can visualize and quantify somatostatin receptor expression in vivo through single-photon emission computed tomography (SPECT). This technique provides critical insights into tumor localization, receptor density, and metastatic spread, particularly in neuroendocrine tumors (NETs) such as carcinoid tumors, gastrinomas, and insulinomas.
The peptide’s high affinity for somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5) underpins its imaging precision. This receptor selectivity allows researchers to map receptor distribution in various tissues, evaluate receptor internalization kinetics, and assess the biological behavior of receptor-positive malignancies.
Structurally, Pentetreotide retains the cyclic octapeptide backbone of Octreotide but incorporates a DTPA moiety at its N-terminus. This chelating group stably binds metallic radioisotopes, enabling controlled synthesis of radiopharmaceutical derivatives.
Pentetreotide | CAS 138661-02-6 | Radiolabeled Somatostatin Analog for Neuroendocrine Tumor Imaging
Product Description
Pentetreotide is a synthetic peptide conjugated with diethylenetriaminepentaacetic acid (DTPA), engineered to facilitate chelation with radioisotopes such as indium-111 for molecular imaging applications. Functionally, it mimics the pharmacological properties of somatostatin, a natural peptide hormone that inhibits the release of various growth and neuroendocrine factors.
By radiolabeling Pentetreotide with indium, researchers can visualize and quantify somatostatin receptor expression in vivo through single-photon emission computed tomography (SPECT). This technique provides critical insights into tumor localization, receptor density, and metastatic spread, particularly in neuroendocrine tumors (NETs) such as carcinoid tumors, gastrinomas, and insulinomas.
The peptide’s high affinity for somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5) underpins its imaging precision. This receptor selectivity allows researchers to map receptor distribution in various tissues, evaluate receptor internalization kinetics, and assess the biological behavior of receptor-positive malignancies.
Structurally, Pentetreotide retains the cyclic octapeptide backbone of Octreotide but incorporates a DTPA moiety at its N-terminus. This chelating group stably binds metallic radioisotopes, enabling controlled synthesis of radiopharmaceutical derivatives.